Format
Sort by

Send to

Choose Destination

Search results

Items: 11

1.

Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians.

Spadi R, Brusa F, Ponzetti A, Chiappino I, Birocco N, Ciuffreda L, Satolli MA.

World J Clin Oncol. 2016 Feb 10;7(1):27-43. doi: 10.5306/wjco.v7.i1.27. Review.

2.

Expression analysis of genes involved in DNA repair or synthesis in mixed neuroendocrine/nonneuroendocrine carcinomas.

Volante M, Monica V, Birocco N, Brizzi MP, Busso S, Daniele L, La Rosa S, Righi L, Sapino A, Berruti A, Scagliotti GV, Papotti M.

Neuroendocrinology. 2015;101(2):151-60. doi: 10.1159/000375449.

PMID:
25633872
3.

Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study.

Berruti A, Fazio N, Ferrero A, Brizzi MP, Volante M, Nobili E, Tozzi L, Bodei L, Torta M, D'Avolio A, Priola AM, Birocco N, Amoroso V, Biasco G, Papotti M, Dogliotti L.

BMC Cancer. 2014 Mar 14;14:184. doi: 10.1186/1471-2407-14-184.

4.

Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues.

Volante M, Birocco N, Gatti G, Duregon E, Lorizzo K, Fazio N, Scagliotti GV, Papotti M.

Hum Pathol. 2014 Apr;45(4):665-73. doi: 10.1016/j.humpath.2013.03.016. Review.

PMID:
23806528
5.

The effects of Reiki therapy on pain and anxiety in patients attending a day oncology and infusion services unit.

Birocco N, Guillame C, Storto S, Ritorto G, Catino C, Gir N, Balestra L, Tealdi G, Orecchia C, Vito GD, Giaretto L, Donadio M, Bertetto O, Schena M, Ciuffreda L.

Am J Hosp Palliat Care. 2012 Jun;29(4):290-4. doi: 10.1177/1049909111420859.

PMID:
21998438
6.

Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network.

Brizzi MP, Berruti A, Ferrero A, Milanesi E, Volante M, Castiglione F, Birocco N, Bombaci S, Perroni D, Ferretti B, Alabiso O, Ciuffreda L, Bertetto O, Papotti M, Dogliotti L.

BMC Cancer. 2009 Nov 3;9:388. doi: 10.1186/1471-2407-9-388.

7.

Induction chemotherapy followed by concurrent chemoradiotherapy in advanced head and neck squamous cell carcinoma.

Barone C, Grillo R, Dongiovanni D, Birocco N, Rampino M, Redda MG, Garibaldi E, Munoz F, Pecorari G, Cavalot A, Garzinodemo P, Buffoni L, Ciuffreda L, Ricardi U, Cortesina G, Giordano C, Fasolis M, Berrone S, Bertetto O, Schena M.

Anticancer Res. 2008 Mar-Apr;28(2B):1285-91.

8.

Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?

Dongiovanni D, Daniele L, Barone C, Dongiovanni V, Fissore C, Sapino A, Macrì L, Bussolati G, Buffoni L, Gaspari F, Grillo R, Birocco N, Addeo A, Ciuffreda L, Schena M.

Lung Cancer. 2008 Jul;61(1):73-81. doi: 10.1016/j.lungcan.2007.12.007.

PMID:
18243402
9.

Pro-inflammatory cytokines and oxidative stress/antioxidant parameters characterize the bio-humoral profile of early cachexia in lung cancer patients.

Fortunati N, Manti R, Birocco N, Pugliese M, Brignardello E, Ciuffreda L, Catalano MG, Aragno M, Boccuzzi G.

Oncol Rep. 2007 Dec;18(6):1521-7.

PMID:
17982639
10.

Fractionated dose of cisplatin (CDDP) and vinorelbine (VNB) chemotherapy for elderly patients with advanced non-small cell lung cancer: phase II trial.

Buffoni L, Dongiovanni D, Barone C, Fissore C, Ottaviani D, Dongiovanni V, Grillo R, Salvadori A, Birocco N, Schena M, Bertetto O.

Lung Cancer. 2006 Dec;54(3):353-7.

PMID:
17049672
11.

Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.

Schena M, Barone C, Birocco N, Dongiovanni D, Numico G, Colantonio I, Bertetto O.

Cancer Chemother Pharmacol. 2005 Mar;55(3):271-6.

PMID:
15592837
Items per page

Supplemental Content

Loading ...
Support Center